Contralateral prophylactic mastectomy after unilateral breast cancer: A systematic review and meta-analysis

Annals of Surgery

Volumn 260, Issue 6, 2014, Pages 1000-1010

  Fayanju, Oluwadamilola Motunaryo ^a   Stoll, Carolyn R T ^a   Fowler, Susan ^a   Colditz, Graham A ^a,b   Margenthaler, Julie A ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Washington University in St Louis School of Medicine   (United States)

Author keywords

Breast cancer; Mastectomy; Meta analysis; Prevention and control; Systematic review

Indexed keywords

ATTRIBUTABLE RISK; BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CLINICAL PRACTICE; CONTRALATERAL PROPHYLACTIC MASTECTOMY; FAMILY HISTORY; GENETIC RISK; HETEROZYGOTE; HIGH RISK PATIENT; HIGH RISK POPULATION; HUMAN; MASTECTOMY; META ANALYSIS; ONCOGENE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROPHYLACTIC SURGICAL PROCEDURE; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; UNILATERAL BREAST CANCER; BREAST NEOPLASMS; FEMALE; HEALTH; INCIDENCE; NEOPLASM RECURRENCE, LOCAL; PROCEDURES; RISK FACTOR;

BREAST NEOPLASMS; FEMALE; GLOBAL HEALTH; HUMANS; INCIDENCE; MASTECTOMY; NEOPLASM RECURRENCE, LOCAL; RISK FACTORS;

EID: 84922318861     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0000000000000769     Document Type: Review

References (82)

1. Tuttle T, Habermann E, Abraham A, et al. Contralateral prophylactic mastectomy for patients with unilateral breast cancer. Expert Rev Anticancer Ther. 2007;7: 1117-1122.
2. Abbott A, Rueth N, Pappas-Varco S, et al. Perceptions of contralateral breast cancer: An overestimation of risk. Ann Surg Oncol. 2011;18: 3129-3136.
3. ChaudhryA, SahuA. Patient request for contralateral prophylactic mastectomy is due to a false perception of increased risk at time of initial diagnosis. Eur J Cancer Suppl. 2010;8: 126; number 233.
4. Giuliano AE, Boolbol S, Degnim AC, et al. Society of surgical oncology: Position statement on prophylactic mastectomy. Ann Surg Oncol. 2007;14: 2425-2427.
5. Schwartz MD, Lerman C, Brogan B, et al. Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients. J Clin Oncol. 2004;22: 1823-1829.
6. Chung A, Huynh K, Lawrence C, et al. Comparison of patient characteristics and outcomes of contralateral prophylactic mastectomy and unilateral total mastectomy in breast cancer patients. Ann Surg Oncol. 2012;19: 2600-2606.
7. Manson J, Brooks SE, Hembree T, et al. Exploratory study of contralateral prophylactic mastectomy in women with breast cancer: Potential role for preoperative genetic counseling. Cancer Prev Res (Phila). 2010;3: B6.
8. Yi M, Hunt KK, Arun BK, et al. Factors affecting the decision of breast cancer patients to undergo contralateral prophylactic mastectomy. Cancer Prevent Res. 2010;3: 1026-1034.
9. Arrington A, Jarosek S, VirnigB, et al. Patient and surgeon characteristics associated with increased use of contralateral prophylactic mastectomy in patients with breast cancer. Ann Surg Oncol. 2009;16: 2697-2704.
10. Nichols HB, Berrington de Gonzalez A, Lacey JV, et al. Declining incidence of contralateral breast cancer in the United States from 1975 to 2006. J Clin Oncol. 2011;29: 1564-1569.
11. Heron DE, Komarnicky LT, Hyslop T, et al. Bilateral breast carcinoma: Risk factors and outcomes for patients with synchronous andmetachronous disease. Cancer. 2000;88: 2739-2750.
12. Obedian E, Fischer D, Haffty B. Second malignancies after treatment of earlystage breast cancer: Lumpectomy and radiation therapy versus mastectomy. J Clin Oncol. 2000;18: 2406-2412.
13. McDonnell S, Schaid D, Myers J, et al. Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. J Clin Oncol. 2001;19: 3938-3943.
14. Graeser MK, Engel C, Rhiem K, et al. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2009;27: 5887-5892.
15. Reiner AS, John EM, Brooks JD, et al. Risk of asynchronous contralateral breast cancer in noncarriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: A report from theWomen's Environmental Cancer and Radiation Epidemiology Study. J Clin Oncol. 2013;31: 433-439.
16. Peralta EA, Ellenhorn JDI, Wagman LD, et al. Contralateral prophylactic mastectomy improves the outcome of selected patients undergoing mastectomy for breast cancer. Am J Surg. 2000;180: 439-445.
17. Bedrosian I, Hu C, Chang G. Population-based study of contralateral prophylactic mastectomy and survival outcomes of breast cancer patients. J Natl Cancer Inst. 2010;102: 401-409.
18. Boughey J, Hoskin T, Degnim A, et al. Contralateral prophylactic mastectomy is associated with a survival advantage in high-risk women with a personal history of breast cancer. Ann Surg Oncol. 2010;17: 2702-2709.
19. Herrinton LJ, Barlow WE, Yu O, et al. Efficacy of prophylactic mastectomy in women with unilateral breast cancer: A cancer research network project. J Clin Oncol. 2005;23: 4275-4286.
20. Jones NB, Wilson J, Kotur L, et al. Contralateral prophylactic mastectomy for unilateral breast cancer: An increasing trend at a single institution. Ann Surg Oncol. 2009;16: 2691-2696.
21. Kiely BE, Jenkins MA, McKinley JM, et al. Contralateral risk-reducing mastectomy in BRCA1 and BRCA2mutation carriers and other high-riskwomen in the Kathleen Cunningham Foundation Consortium for Research into Familial Breast Cancer (kConFab). Breast Cancer Res Treat. 2010;120: 715-723.
22. Lee JS, Grant CS, Donohue JH, et al. Arguments against routine contralateral mastectomy or undirected biopsy for invasive lobular cancer. Surgery. 1995;118: 640-647; discussion 647-648.
23. Metcalfe K, Lynch HT, Ghadirian P, et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2004;22: 2328-2335.
24. Van Sprundel TC, Schmidt MK, Rookus MA, et al. Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers. Br J Cancer. 2005;93: 287-292.
25. Lostumbo L, Carbine NE, Wallace J. Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst Rev. 2010;(3): CD002748. Available at: Http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD 00274/frme.html; and http://onlinelibrary.wiley.com/store/10.1002/14651858. CD002748.pub3/asset/CD002748.pdf?v=1&t=h406p1vl&s=0849c49574aa 5139e9d87d6939618fc773adc340. Accessed March 1, 2014.
26. King TA, SakrR, Patil S, et al. Clinical management factors contribute to the decision for contralateral prophylactic mastectomy. J Clin Oncol. 2011;29: 2158-2164.
27. Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Commun Health. 1998;52: 377-384.
28. Heemskerk-Gerritsen BAM, Hooning MJ, Jager A, et al. Is risk-reducing mastectomy in BRCA1/2mutation carrierswith a history of unilateral breast cancer beneficial with respect to distant disease free survival and overall survival? Eur J Cancer Suppl. 2010;8: 206.
29. BarryM, SacchiniV.When is contralateralmastectomywarranted in unilateral breast cancer? Expert Rev Anticancer Ther. 2011;11: 1209-1214.
30. Brewster AM, Parker PA. Current knowledge on contralateral prophylactic mastectomy among women with sporadic breast cancer. Oncologist. 2011;16: 935-941.
31. de la Pena-Salcedo JA, Soto-Miranda MA, Lopez-Salguero JF. Prophylactic mastectomy: Is it worth it? Aesthetic Plast Surg. 2012;36: 140-148.
32. Gershenwald JE, Hunt KK, Kroll SS, et al. Synchronous elective contralateral mastectomy and immediate bilateral breast reconstruction inwomen with earlystage breast cancer. Ann Surg Oncol. 1998;5: 529-538.
33. Morrow M. Prophylactic contralateral surgery: Current recommendations and techniques. Breast Cancer Res. 2009;11: S4.
34. Nekhlyudov L, Bower M, Herrinton LJ, et al. Women's decision-making roles regarding contralateral prophylactic mastectomy. J Natl Cancer Inst Monogr. 2005: 55-60.
35. Newman LA, Kuerer HM, Hung KK, et al. Prophylactic mastectomy. J Am Coll Surg. 2000;191: 322-330.
36. Schrag D, Kuntz KM, Garber JE, Weeks JC. Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations. JAMA. 2000;283: 617-624.
37. Tuttle TM, AbbottA, Arrington A, RuethN. The increasing use of prophylactic mastectomy in the prevention of breast cancer. Curr Oncol Rep. 2010;12: 16-21.
38. Yao K, Stewart AK, Winchester DJ, Winchester DP. Trends in contralateral prophylactic mastectomy for unilateral cancer: A report from the National Cancer Data Base, 1998-2007. Ann Surg Oncol. 2010;17: 2554-2562.
39. Zendejas B, Moriarty JP, O'Byrne J, et al. Cost-effectiveness of contralateral prophylactic mastectomy versus routine surveillance in patients with unilateral breast cancer. J Clin Oncol. 2011;29: 2993-3000.
40. Frost M, Slezak JM, Tran N, et al. Satisfaction after contralateral prophylactic mastectomy: The significance of mastectomy type, reconstructive complications, and body appearance. J Clin Oncol. 2005;23: 7849-7856.
41. Babiera GV, Lowy AM, Davidson BS, et al. The role of contralateral prophylactic mastectomy in invasive lobular carcinoma. Breast J. 1997;3: 2-6.
42. Boughey J, Khakpour N, Meric-Bernstam F, et al. Selective use of sentinel lymph node surgery during prophylactic mastectomy. Cancer. 2006;107: 1440-1447.
43. King T, Gurevich I, Sakr R, et al. Occult malignancy in patients undergoing contralateral prophylactic mastectomy. Ann Surg. 2011;254: 2-7.
44. Montgomery L, Tran K, Heelan M, et al. Issues of regret in women with contralateral prophylactic mastectomies. Ann Surg Oncol. 1999;6: 546-552.
45. Goldflam K, Hunt KK, Gershenwald JE, et al. Contralateral prophylactic mastectomy predictors of significant histologic findings. Cancer. 2004;101: 1977-1986.
46. Metcalfe KA, Lubinski J, Ghadirian P, et al. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: The Hereditary Breast Cancer Clinical Study Group. J Clin Oncol. 2008;26: 1093-1097.
47. Verhoog LC, Brekelmans CT, Seynaeve C, et al. Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet. 1998;351: 316-321.
48. Verhoog LC, Brekelmans CTM, Seynaeve C, et al. Survival in hereditary breast cancer associated with germline mutations of BRCA2. J Clin Oncol. 1999;17: 3396-3402.
49. Chen Y, Thompson W, Semenicw R, et al. Epidemiology of contralateral breast cancer. Cancer Epidemiol Biomarkers Prev. 1999;8: 855-861.
50. Tuttle T, Habermann E, Grund E, et al. Increasing use of contralateral prophylactic mastectomy for breast cancer patients: A trend toward more aggressive surgical treatment. J Clin Oncol. 2007;25: 5203-5209.
51. Warner E, Hill K, Causer P, et al. Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging. J Clin Oncol. 2011;29: 1664-1669.
52. Buzdar A, Hunt K, Buchholz TA, et al. Improving survival of patients with breast cancer over the past 6 decades: The University of Texas M. D. Anderson Cancer Center experience. Paper presented at: American Society of Clinical Oncology (ASCO) Breast Cancer Symposium; October 2, 2010; National Harbor, MD.
53. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81: 1879-1886.
54. Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med. 2004;23: 1111-1130.
55. Olkin I, Sampson A. Comparison of meta-Analysis versus analysis of variance of individual patient data. Biometrics. 1998;54: 317-322.
56. McLaughlin C, Lillquist P, Edge S. Surveillance of prophylactic mastectomy: Trends in use from 1995 through 2005. Cancer. 2009;115: 5404-5412.
57. Khan SA. Contralateral prophylactic mastectomy: What do we know and what do our patients know? J Clin Oncol. 2011;29: 2132-2135.
58. Vichapat V, Garmo H, Holmqvist M, et al. Tumor stage affects risk and prognosis of contralateral breast cancer: Results from a large Swedish-populationbased study. J Clin Oncol. 2012;30: 3478-3485.
59. Gao X, Fisher S, Emami B. Risk of second primary cancer in the contralateral breast inwomen treated for early-stage breast cancer: A population-based study. Int J Radiat Oncol Biol Phys. 2003;56: 1038-1045.
60. Bertelsen L, Bernstein L, Olsen JH, et al. Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the women's environment, cancer and radiation epidemiology study. J Natl Cancer Inst. 2008;100: 32-40.
61. Kiess AP, McArthur HL, Mahoney K, et al. Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer. Cancer Causes Control. 2012;118: 1982-1988.
62. Smith I, ProcterM, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial. The Lancet. 2012;369: 29-36.
63. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90: 1371-1388.
64. Coopey SB, Mazzola E, Buckley JM, et al. The role of chemoprevention in modifying the risk of breast cancer in women with atypical breast lesions. Breast Cancer Res Treat. 2012;136: 627-633.
65. Disparities in breast cancer screening. Available at: Http://ww5.komen.org/BreastCancer/RacialEthnicIssuesinScreening.html. Accessed 30 November 2012.
66. Bedrosian I, Mick R, Orel S, et al. Changes in the surgical management of patients with breast carcinoma based on preoperative magnetic resonance imaging. Cancer. 2003;98: 468-473.
67. Biglia N, Bounous V, Martincich L, et al. Role of MRI (magnetic resonance imaging) versus conventional imaging for breast cancer presurgical staging in young women or with dense breast. Eur J Surg Oncol. 2011;37: 199-204.
68. Bilimoria K, Cambic A, Hansen N, et al. Evaluating the impact of preoperative breast magnetic resonance imaging on the surgical management of newly diagnosed breast cancers. Arch Surg. 2007;142: 441-445.
69. Lehman CD, Gatsonis C, Kuhl CK, et al. MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer. N Engl J Med. 2007;356: 1295-1303.
70. Slanetz P, EdmisterW, Yeh E, et al. Occult contralateral breast carcinoma incidentally detected by breastmagnetic resonance imaging. Breast J. 2002;8: 145-148.
71. Smith R. The evolving role of MRI in the detection and evaluation of breast cancer. N Engl J Med. 2007;356: 1364-1364.
72. Sorbero M, Dick A, Beckjord E, et al. Diagnostic breast magnetic resonance imaging and contralateral prophylactic mastectomy. Ann Surg Oncol. 2009;16: 1597-1605.
73. Fitzgibbons PL, Page DL, Weaver D, et al. Prognostic factors in breast cancer. Arch Pathol Lab Med. 2000;124: 966-978.
74. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24, 740 breast cancer cases. Cancer. 1989;63: 181-187.
75. Richards M, Westcombe A, Love S, et al. Influence of delay on survival in patients with breast cancer: A systematic review. Lancet. 1999;353: 1119-1126.
76. Gentry S, Davis DL. Influencing factors for a contralateral prophylactic mastectomy. Am J Clin Oncol. 2011;34: 550.
77. Bresser P, Seynaeve C, Van Gool A, et al. Satisfaction with prophylactic mastectomy and breast reconstruction in genetically predisposed women. Plast Reconstr Surg. 2006;117: 1675-1682.
78. Contant C, Menke-Pluijmers M, Seynaeve C, et al. Clinical experience of prophylactic mastectomy followed by immediate breast reconstruction in women at hereditary risk of breast cancer (HB(O)C) or a proven BRCA1 and BRCA2 germ-line mutation. Eur J Surg Oncol. 2002;28: 627-632.
79. Geiger A, West C, Nekhlyudov L, et al. Contentment with quality of life among breast cancer survivors with and without contralateral prophylactic mastectomy. J Clin Oncol. 2006;24: 1350-1356.
80. Schwartz MD. Contralateral prophylactic mastectomy: Efficacy, satisfaction, and regret. J Clin Oncol. 2005;23: 7777-7779.
81. Tercyak K, Peshkin B, Brogan B, et al. Quality of life after contralateral prophylactic mastectomy in newly diagnosed high-risk breast cancer patients who underwent BRCA1/2 gene testing. J Clin Oncol. 2007;25: 285-291.
82. Anders CK, Hsu DS, Broadwater G, et al. Young age at diagnosis correlates withworse prognosis and defines a subset of breast cancerswith shared patterns of gene expression. J Clin Oncol. 2008;26: 3324-3330.